Abstract Library

#4662 A novel hormone based anti-SSTR anti-CD3 T-cell engager for the treatment of neuroendocrine tumours

Introduction: Somatostatin receptor 2 (SSTR2) is overexpressed in well-differentiated NETs.

Conference:

Presenting Author: Pelle E

Authors: Pelle E, Cives M, Chaoul N, d'Angelo G, Medina E,

Keywords: T-cell engager, immunotherapy, tumouroids,

#4384 The efficacy of combination of temozolomide and capecitabine for neuroendocrine tumours: A real-world comparison of outcomes in Alberta, Canada – Patients treated from 2011-2021

Introduction: The combination of capecitabine and temozolomide (CAPTEM) showed PFS benefits in pancreatic neuroendocrine tumours (PNETs).

Conference:

Presenting Author:

Authors: Aleksi A, Malek H, Husi P, Halperin H, White-Gloria C,

Keywords: captem, neuroendocrine tumour, endocrine tumour, progression-free survival, overall survival,

#4120 Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH): An international case series

Introduction: Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) is a rare disorder that is characterized by diffuse hyperplasia of bronchiolar and bronchial pulmonary neuroendocrine cells. The precise incidence and prevalence is unknown and the clinical course is not fully understood.

Conference:

Presenting Author: Almeamar H

Authors: Penugonda M, O'Callaghan M, Diesler R, O'Brien H, Almeamar H,

Keywords: DIPNECH, NET, neuroendocrine, pulmonary NET, Neuroendocrine cells hyperplasia,

#4088 Ex vivo expansion of TILs from panNET liver metastasis: In search of novel adoptive transfer strategies for the treatment of NETs

Introduction: It is unknown whether tumor infiltrating lymphocytes (TILs) from NETs may be an effective treatment in patients with NETs.

Conference:

Presenting Author: Chaoul N

Authors: Chaoul N, d'Angelo G, Giglio A, Mandriani B, Matrella M,

Keywords: panNET, TILs, adoptive T cell therapy, neoantigen-reactive TILs,

#3885 Adaptive immunosuppressive resistance mechanisms towards antiangiogenic immunotherapies revealed in a pancreatic neuroendocrine tumor (PNET) model

Introduction: Pancreatic neuroendocrine tumors (PNETs) are mostly indolent but can achieve malignancy. Surgery is the only approved first-line therapy. Kinase inhibitors and radiotherapy for unresectable PNETs are non-curative and targeted therapies are currently lacking for PNETs. However, immune checkpoint inhibitors have created a paradigm shift in cancer therapy with significant increase in overall survival, but are curative only in a subset of patients, partly due to limited T cell infiltration, especially in angiogenic and cold tumors like PNETs. Parallelly, antiangiogenic therapy increases lymphocyte infiltration by normalising the tumor vasculature. Tallying antiangiogenic to immunotherapies (AI) has provided improved survival benefits for patients of advanced RCCs and HCCs, while other cancers like glioblastoma remain highly resistant.

Conference:

Presenting Author:

Authors: John Robbert D, Guyot M, Killian T, Verslype C, Lambrechts D,

Keywords: Pancreatic neuroendocrine tumor, Antiangiogenic immunotherapy, single cell transcriptomics, Immunosuppression,